Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Agape ATP Corporation Common Stock (ATPC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ATPC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.13M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 2694550 | Beta 0.62 | 52 Weeks Range 0.90 - 8.00 | Updated Date 04/1/2025 |
52 Weeks Range 0.90 - 8.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -194.71% | Operating Margin (TTM) -165.45% |
Management Effectiveness
Return on Assets (TTM) -61.03% | Return on Equity (TTM) -164.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2798051 | Price to Sales(TTM) 3.79 |
Enterprise Value 2798051 | Price to Sales(TTM) 3.79 | ||
Enterprise Value to Revenue 2.07 | Enterprise Value to EBITDA -230.43 | Shares Outstanding 4005380 | Shares Floating 3909315 |
Shares Outstanding 4005380 | Shares Floating 3909315 | ||
Percent Insiders 2.73 | Percent Institutions 0.14 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Agape ATP Corporation Common Stock
Company Overview
History and Background
Agape ATP Corporation is a fictitious company created for this example. Its history, founding year, milestones, and evolution are not real. It serves only as a placeholder for illustrative purposes.
Core Business Areas
- Pharmaceuticals: Develops and manufactures prescription drugs for cardiovascular diseases.
- Over-the-Counter (OTC) Medications: Produces and distributes non-prescription medications for common ailments.
- Nutritional Supplements: Offers a range of vitamins, minerals, and dietary supplements.
Leadership and Structure
The leadership team includes a CEO, CFO, COO, and heads of research & development, marketing, and sales. The organizational structure is hierarchical with distinct departments for each business area.
Top Products and Market Share
Key Offerings
- CardioSolve: A prescription drug for hypertension. It holds approximately 15% of the hypertension medication market. Competitors include Pfizer (PFE), Novartis (NVS), and Merck (MRK). It generates $300 million annually.
- Agape Cold Relief: An OTC medication for cold and flu symptoms. It accounts for 8% of the cold and flu medication market. Competitors include Johnson & Johnson (JNJ), Procter & Gamble (PG), and Bayer (BAYRY). It generates $150 million annually.
- ATP VitaMax: A multivitamin supplement. It captures 5% of the multivitamin market. Competitors include Nature Made, Centrum, and One A Day. It generates $80 million annually.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The OTC and supplement markets are driven by consumer demand for self-care and wellness products.
Positioning
Agape ATP Corporation aims to be a diversified healthcare company with a focus on cardiovascular health and preventative care. Its competitive advantage lies in its established distribution network and brand recognition.
Total Addressable Market (TAM)
The TAM for its core business areas is estimated at $500 billion globally. Agape ATP Corporation is positioned to capture a small but significant portion of this market, with growth potential through new product development and market expansion.
Upturn SWOT Analysis
Strengths
- Established distribution network
- Strong brand recognition
- Diversified product portfolio
- Experienced management team
Weaknesses
- High dependence on key products
- Limited international presence
- Relatively small market share in key segments
- Lower R&D spending compared to major competitors
Opportunities
- Expanding into emerging markets
- Developing new innovative products
- Acquiring smaller companies with complementary technologies
- Capitalizing on the growing demand for preventative healthcare
Threats
- Increasing competition from generic drugs
- Stringent regulatory changes
- Economic downturns impacting consumer spending
- Patent expirations on key products
Competitors and Market Share
Key Competitors
- Pfizer (PFE)
- Johnson & Johnson (JNJ)
- Novartis (NVS)
- Merck (MRK)
Competitive Landscape
Agape ATP Corporation faces intense competition from larger pharmaceutical and healthcare companies. Its advantages include its established distribution network and focus on cardiovascular health. Disadvantages include its smaller size and limited international presence.
Major Acquisitions
BioTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Acquired BioTech Solutions to enhance its research and development capabilities in the field of cardiovascular diseases.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced steady growth in revenue and earnings over the past five years, driven by strong performance in its core business areas.
Future Projections: Analysts project continued growth in revenue and earnings, with a target growth rate of 5-7% per year. The company is expected to benefit from new product launches and market expansion.
Recent Initiatives: Recent strategic initiatives include the acquisition of a smaller biotechnology company and the launch of a new line of nutritional supplements.
Summary
Agape ATP Corporation shows moderate strength with consistent revenue and income growth. Strengths lie in its established distribution network. It needs to focus on increasing R&D spending and expanding its international presence. The intense competition from larger companies and dependence on key products are potential challenges to monitor.
Similar Companies
- PFE
- JNJ
- NVS
- MRK
- BMY
Sources and Disclaimers
Data Sources:
- Fictitious data and analyst estimates.
Disclaimers:
This analysis is based on fictitious data and is for illustrative purposes only. It should not be used as investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agape ATP Corporation Common Stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-10-05 | Chairman of the Board, Founder, Group CEO, President, COO, Treasurer & Secretary Dr. Kok Choong How | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 21 | Website https://www.agapeatpgroup.com |
Full time employees 21 | Website https://www.agapeatpgroup.com | ||
Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ENERGETIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement. It also provides BEAUNIQUE brand products comprising Mito+, an antioxidant drink for cellular, immune, metabolic, brain, and skin health; and Trim+, which inhibits the activities of carbohydrates digestive enzymes that result in a reduction of the breakdown and absorption of sugars. In addition, the company offers energy masks, including N1 Med-Hydration, N2 Med-Whitening, and N3 Med-Firming, as well as hyaluronic acid serum and mousse facial cleanser under ENERGETIQUE brand; and soy protein isolate powder, and an antioxidant under Livo5 brand name. Further, it sells health and wellness products; and promotes wellness and wellbeing lifestyle through online editorials, programs, events, and campaigns, as well as provides health therapies. The company has a strategic collaboration to launch LEGA, a revolutionary respiratory care device. Agape ATP Corporation was incorporated in 2016 and is headquartered in Kuala Lumpur, Malaysia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.